Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Someone wants out at any cost again..... Going to be this pattern until data...
Not expecting results until mid November... Has IPIX ever delivered anything on a time reference? By time B would be approved the pandemic will be over.
The end of the road for Leo. He made millions for himself and millions in losses for his shareholders. What a financial system award the crooks.
Focus will soon shift back to OM/K/UP/AS/Locust Walk!!! Lets go back in time and recapture the past 2 years!!! Covid bought Leo another 2 years to play pretend CEO and biotech.
Where did all the pumpers go who thought the chart was in a positive trend? LOL Today's Merck news just reversed the trend....
Correct, with the virus winding down and other solutions on the horizon B for C was critical to the immediate survival of IPIX... Some posting here believe there's all-the-time in the World to test B or run a phase 3....
Leo tried to play big boy biotech in his swimmies.
It's dropping because there's other therapeutics hitting the market soon... Unless Leo gets emergency use data will not matter... A phase 3 is not in-the-cards... Been saying this for a year... The costs and time to complete would not be worth the revenue potential which is a big fat DON'T KNOW or HAVE a CLUE...
Leo can tap Aspire at 5 pennies to pay for B OM phase 3.... That will be comical...
There won't be a market for B injection if there's a pill solution. Almost 2 years wasted on B for C games...
Leo packed his bags months ago... The 10K showed no expansion under-way just the same 2 person crew riding out the few months remaining.
Bogus, this stock rallied past .50 three times last year but now that they're close to data it can't sustain .30? The reason why this stock is dead money is because Leo missed the boat. A phase 3 would not make any sense to complete a year from now... Nobody will partner so it will be back to OM/UP to save the day...
That's great if IPIX had other revenues to keep testing B for a decade... Leo threw all his marbles at B for C the past 18 months.. We'll see if he gets any return on his investment... .24 is pathetic......
Sitting at .24 speaks volumes... If Leo was in this position a year ago the stock would be 2 bucks anticipating data. A year later cases are finally in a major down swing, new therapeutics (pill)) are a few months away... The last 10K did not bring much joy....
Price ready to sink to the .23's... With Delta cases dropping quick and pill therapeutics available soon P2 better be a homerun.
Yes and resorting back to OM/UP/K will not be enough to keep them afloat... They ditched all of them for 2 years playing the COVID card... Alpgasigma is stringing Leo along and Locust Walk could not find anyone interested in OM... K was dead once Menon left...
There's an active seller who continues to move the ask lower immediately once his order is filled... So obvious it's Leo's lenders... Pick one of the two...
Finally there will be an end to this madness... Believe IPIX will be sold or have to dissolve like Polymedix. P2 data will be the decision maker... The 10K showed little excitement for Leo building the company onward...
4 weeks until judgement Day place your bets... 24 cents per lottery game...
You must be attracting shorts or those not interested judging the 3 month chart... .24 is pathetic...
Kips/Aspire competing for the ask all day, every bid above .25 gets eaten alive....
No interest left in this stock the 10K scared all buyers away... Next catalyst will be a lock PR...
The best IPIX can do is an indirect grant payment to GMU? That should move this stock an 1/8 of a penny...
Pfizer CEO and others hinting the Virus's end in a year. Leo will be shifting focus back to OM/UP... Like others have stated unless they get Emergency Use the past 2 years will be for not... They could have had the OM trial done...
Why was yesterdays 10K good news? It was a rehash of the past 4 filings... Only difference results are due out within a month, Aspire funding is available and AS/OM gets delayed to 2022... That's about it...
Most likely the last safety check was for compassionate use because the trial was already completed around that time...
Why wasn't OM phase 3 started this year? What's another 6 month wait going to change? They have Aspire's 25 million sitting there... The only logic is hoping the PPS rises to offset dilution.. Again, everything rides on good data to prop the PPS up... Yesterday's 10K confirms why Leo's been silent... Nothing going on except B for C... Alphasigma another joke, they couldn't manufacture B for a year? LOL more excuses...
New section on emergency use (FDA and outside regions)
Newly emerging SARS-CoV-2 variants could reduce the effectiveness of Brilacidin as a potential COVID-19 treatment.
Multiple variants of the virus that causes COVID-19 have been documented in the United States and globally during this pandemic. While Brilacidin is showing an ability in vitro to be resistant to SARS-CoV-2 mutations, the compound might not continue to do so based on the potential emergence of new variants in the future.
There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. If we do not apply for such an authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the new drug licensure process in order to sell our product, which is lengthy and expensive.
We may seek an Emergency Use Authorization, or EUA, from the FDA or similar authorization from regulatory authorities outside of the United States, such as conditional marketing authorization from the EMA. If we apply for an EUA and it is granted, an EUA will authorize us to market and sell our COVID-19 treatment under certain conditions of authorization as long as the public health emergency exists. The FDA expects that companies which receive an EUA for COVID-19 treatments will proceed to licensure of their products under a full New Drug Application (NDA). The FDA may issue an EUA during a Public Health Emergency if the agency determines that the potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. There is no guarantee that we will apply for an EUA or other similar authorization or, if we do apply, that we will be able to obtain such authorization. If an EUA or other authorization is granted, we will rely on the FDA or other applicable regulatory authority policies and guidance governing treatments authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. An EUA authorizing the marketing and sale of our product will terminate upon expiration of the Public Health Emergency, which is a determination made by the Secretary of Health and Human Services. The FDA may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of authorization. If we apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our COVID-19 treatment, which could adversely impact our business, financial condition and results of operations.
Alphasigma pushed back to 2022, vendor delays in manufacturing... Seems a bit odd...
In January 2021, Alfasigma notified the Company that the Phase 1 study for the treatment of UP/UPS using Brilacidin in a proprietary Alfasigma formulation successfully completed dosing per protocol; an extra treatment cohort was subsequently added by amendment and commenced in 2Q 2021. In April 2021, the Company was notified that a Phase 2 multinational clinical trial for UP/UPS is planned to commence 4Q 2021, and Alfasigma has ordered Brilacidin from the Company for use in this study. Due to a delay at the manufacturing vendor, delivery of drug substance to Alfasigma has moved out (mid 4Q2021), and the subsequent drug product manufacturing time will likely push any clinical trial start into 2022.
Yes, we won't know how much the CRO is still owed but 11 million on top of Aspire's 24 million is a nice amount if they can move the stock price higher to limit dilution. Everything rides on data...
Aspire's 25.4 million still alive....
The Company will be unable to proceed with its planned drug development programs, meet its administrative expense requirements, capital costs, or staffing costs without accessing its financing available with Aspire Capital of approximately $30 million, of which approximately $25.4 million remains as of the date of this filing.
Nice read on Right to Try and it's history....
https://ascopubs.org/doi/full/10.1200/OP.20.00569
Agree, as long as they're still alive it's a good sign not knowing the facts... If they strictly used B that's potentially more profit than a combo with Remdesivir... Appears that's the case... We'll see if Leo provides an update?
There's no mention because IPIX does not have a tablet form currently prepared or from their just completed trial. They've tested B in a small sample see below P1 in 2019....
http://www.ipharminc.com/press-release/2020/1/24/innovation-pharmaceuticals-completes-dosing-in-phase-1-trial-for-new-oral-ulcerative-colitis-drug
http://www.ipharminc.com/press-release/2020/2/13/innovation-pharmaceuticals-phase-1-trial-of-brilacidin-for-ulcerative-colitis-meets-primary-endpoints-positive-topline-results-of-oral-brilacidin
Topline data is expected shortly and includes the safety, tolerability and pharmacokinetics of the Brilacidin tablets. Importantly, the results also include an assessment of the delivery of Brilacidin directly to the colon as determined through gamma scintigraphy.
The Company has partnered with BDD Pharma to utilize their proprietary OralogiK™ technology, an unrivalled erosion-based technology that controls the release of the drug at a pre-defined time. Additional information on this leading technology can be found on the BDD Pharma website.
IPIX is currently valued around 100 million. Isn't that fair until we see results? Not bad for 2 employees and how much cash left? 3 or 4 million...
Leo was able to PR it was currently in use... Should be able to report progress...
Leo needs capital for 2022 it's Kips or another newbie he's found...
Rally killer 360K at .254, Thanks Kips!!!!